drugset / Trial / NCT06212960
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
Timeline
- Start
- 2023-11-28
- Primary completion
- 2024-02-26
- Completion
- 2024-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | Intramuscular |
| Subject | DWP712 | Unknown | 20 iu | Intramuscular |
Indications
No indication recorded.